



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/767,638
	Filing Date	January 29, 2004
	First Named Inventor	Paul S. Charifson
	Group Art Unit	1625
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	VPI/02-128 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
CC	B1	WO	02/060879	Vertex Pharmaceuticals, Inc.	8 August 2002	<input checked="" type="checkbox"/>	<input type="checkbox"/>
CC	B2	WO	03/105846	Vertex Pharmaceuticals, Inc.	24 December 2003	<input checked="" type="checkbox"/>	<input type="checkbox"/>

OTHER NONPATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
CC	C1	Kus et al., "Synthesis and Antimicrobial Activities of 5-fluoro-1,2,6-trisubstituted Benzimidazole Carboxamide and Acetamide Derivatives" Arch. Pharm. Pharm. Med. Chem., Vol. 334, No. 11, Pages 361-365, 2001.
CC	C2	Sun et al., "Synthesis and Evaluation of Terbenzimidazoles as Topoisomerase I Inhibitors" J. Med. Chem., Vol. 38, No. 18, Pages 3638-3644, 1995.
CC	C3	Hubschwerlen et al., "Pyrimido[1,6-a]benzimidazoles: A New Class of DNA Gyrase Inhibitors" J. Med. Chem, Vol. 35, No. 8, Pages 1385-1392, 1992.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Celia Chang/	Date Considered	02/05/2007
--------------------	---------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.